Complement and MHC patterns can provide the diagnostic framework for inflammatory neuromuscular diseases.
Complement
Major histocompatibility complex
Muscle dystrophies
Myasthenia gravis
Myositis
Journal
Acta neuropathologica
ISSN: 1432-0533
Titre abrégé: Acta Neuropathol
Pays: Germany
ID NLM: 0412041
Informations de publication
Date de publication:
12 Jan 2024
12 Jan 2024
Historique:
received:
29
08
2023
accepted:
12
12
2023
revised:
12
12
2023
medline:
12
1
2024
pubmed:
12
1
2024
entrez:
12
1
2024
Statut:
epublish
Résumé
Histopathological analysis stands as the gold standard for the identification and differentiation of inflammatory neuromuscular diseases. These disorders continue to constitute a diagnostic challenge due to their clinical heterogeneity, rarity and overlapping features. To establish standardized protocols for the diagnosis of inflammatory neuromuscular diseases, the development of cost-effective and widely applicable tools is crucial, especially in settings constrained by limited resources. The focus of this review is to emphasize the diagnostic value of major histocompatibility complex (MHC) and complement patterns in the immunohistochemical analysis of these diseases. We explore the immunological background of MHC and complement signatures that characterize inflammatory features, with a specific focus on idiopathic inflammatory myopathies. With this approach, we aim to provide a diagnostic algorithm that may improve and simplify the diagnostic workup based on a limited panel of stainings. Our approach acknowledges the current limitations in the field of inflammatory neuromuscular diseases, particularly the scarcity of large-scale, prospective studies that validate the diagnostic potential of these markers. Further efforts are needed to establish a consensus on the diagnostic protocol to effectively distinguish these diseases.
Identifiants
pubmed: 38214778
doi: 10.1007/s00401-023-02669-8
pii: 10.1007/s00401-023-02669-8
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
15Informations de copyright
© 2024. The Author(s).
Références
Allenbach Y, Anquetil C, Manouchehri A, Benveniste O, Lambotte O, Lebrun-Vignes B et al (2020) Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmun Rev 19:102586. https://doi.org/10.1016/j.autrev.2020.102586
doi: 10.1016/j.autrev.2020.102586
pubmed: 32535094
Allenbach Y, Arouche-Delaperche L, Preusse C, Radbruch H, Butler-Browne G, Champtiaux N et al (2018) Necrosis in anti-SRP+ and anti-HMGCR+myopathies: role of autoantibodies and complement. Neurology 90:e507–e517. https://doi.org/10.1212/WNL.0000000000004923
doi: 10.1212/WNL.0000000000004923
pubmed: 29330311
Allenbach Y, Benveniste O, Stenzel W, Boyer O (2020) Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol 16:689–701. https://doi.org/10.1038/s41584-020-00515-9
doi: 10.1038/s41584-020-00515-9
pubmed: 33093664
Allenbach Y, Leroux G, Suárez-Calvet X, Preusse C, Gallardo E, Hervier B et al (2016) Dermatomyositis with or without anti-melanoma differentiation-associated gene 5 antibodies: common interferon signature but distinct NOS2 expression. Am J Pathol 186:691–700. https://doi.org/10.1016/j.ajpath.2015.11.010
doi: 10.1016/j.ajpath.2015.11.010
pubmed: 26806087
Allenbach Y, Mammen AL, Benveniste O, Stenzel W, Immune-Mediated Necrotizing Myopathies Working Group (2018) 224th ENMC international workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14–16 October 2016. Neuromuscul Disord 28:87–99. https://doi.org/10.1016/j.nmd.2017.09.016
doi: 10.1016/j.nmd.2017.09.016
pubmed: 29221629
Aouizerate J, De Antonio M, Bassez G, Gherardi RK, Berenbaum F, Guillevin L et al (2014) Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy. Acta Neuropathol Commun 2:154. https://doi.org/10.1186/s40478-014-0154-2
doi: 10.1186/s40478-014-0154-2
pubmed: 25339355
pmcid: 4210467
Appleyard ST, Dunn MJ, Dubowitz V, Rose ML (1985) Increased expression of HLA ABC class I antigens by muscle fibres in Duchenne muscular dystrophy, inflammatory myopathy, and other neuromuscular disorders. Lancet 1:361–363. https://doi.org/10.1016/s0140-6736(85)91384-4
doi: 10.1016/s0140-6736(85)91384-4
pubmed: 2857418
Arahata K, Engel AG (1988) Monoclonal antibody analysis of mononuclear cells in myopathies. IV: cell-mediated cytotoxicity and muscle fiber necrosis. Ann Neurol 23:168–173. https://doi.org/10.1002/ana.410230210
doi: 10.1002/ana.410230210
pubmed: 3288082
Becker N, Moore SA, Jones KA (2022) The inflammatory pathology of dysferlinopathy is distinct from calpainopathy, Becker muscular dystrophy, and inflammatory myopathies. Acta Neuropathol Commun 10:17. https://doi.org/10.1186/s40478-022-01320-z
doi: 10.1186/s40478-022-01320-z
pubmed: 35135626
pmcid: 8822795
Benveniste O, Goebel H-H, Stenzel W (2019) Biomarkers in inflammatory myopathies—an expanded definition. Front Neurol 10:554. https://doi.org/10.3389/fneur.2019.00554
doi: 10.3389/fneur.2019.00554
pubmed: 31214105
pmcid: 6558048
Benveniste O, Stenzel W, Allenbach Y (2016) Advances in serological diagnostics of inflammatory myopathies. Curr Opin Neurol 29:662–673. https://doi.org/10.1097/WCO.0000000000000376
doi: 10.1097/WCO.0000000000000376
pubmed: 27538058
Benveniste O, Stenzel W, Hilton-Jones D, Sandri M, Boyer O, van Engelen BGM (2015) Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken. Acta Neuropathol 129:611–624. https://doi.org/10.1007/s00401-015-1384-5
doi: 10.1007/s00401-015-1384-5
pubmed: 25579751
pmcid: 4405277
Bitencourt N, Solow EB, Wright T, Bermas BL (2020) Inflammatory myositis in systemic lupus erythematosus. Lupus 29:776–781. https://doi.org/10.1177/0961203320918021
doi: 10.1177/0961203320918021
pubmed: 32281474
Christiansen J, Güttsches A-K, Schara-Schmidt U, Vorgerd M, Heute C, Preusse C et al (2022) ANO5-related muscle diseases: from clinics and genetics to pathology and research strategies. Genes Dis 9:1506–1520. https://doi.org/10.1016/j.gendis.2022.01.001
doi: 10.1016/j.gendis.2022.01.001
pubmed: 36157496
pmcid: 9485283
Confalonieri P, Oliva L, Andreetta F, Lorenzoni R, Dassi P, Mariani E et al (2003) Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study. J Neuroimmunol 142:130–136. https://doi.org/10.1016/s0165-5728(03)00255-8
doi: 10.1016/s0165-5728(03)00255-8
pubmed: 14512171
Connolly CM, Paik JJ (2023) Clinical pearls and promising therapies in myositis. Expert Rev Clin Immunol 19:797–811. https://doi.org/10.1080/1744666X.2023.2212162
doi: 10.1080/1744666X.2023.2212162
pubmed: 37158055
Cortés-Vicente E, Gallardo E, Álvarez-Velasco R, Illa I (2020) Myasthenia gravis treatment updates. Curr Treat Options Neurol 22:24. https://doi.org/10.1007/s11940-020-00632-6
doi: 10.1007/s11940-020-00632-6
Crockett CD, Ruggieri A, Gujrati M, Zallek CM, Ramachandran N, Minassian BA et al (2014) Late adult-onset of X-linked myopathy with excessive autophagy. Muscle Nerve 50:138–144. https://doi.org/10.1002/mus.24197
doi: 10.1002/mus.24197
pubmed: 24488655
pmcid: 4589296
Dalakas MC (2022) Complement in autoimmune inflammatory myopathies, the role of myositis-associated antibodies, COVID-19 associations, and muscle amyloid deposits. Expert Rev Clin Immunol 18:413–423. https://doi.org/10.1080/1744666X.2022.2054803
doi: 10.1080/1744666X.2022.2054803
pubmed: 35323101
Das L, Blumbergs PC, Manavis J, Limaye VS (2013) Major histocompatibility complex class I and II expression in idiopathic inflammatory myopathy. Appl Immunohistochem Mol Morphol 21:539–542. https://doi.org/10.1097/PAI.0b013e31827d7f16
doi: 10.1097/PAI.0b013e31827d7f16
pubmed: 23343957
de De CamargoCarvalho LVMS, Shinjo SK, de Oliveira ASB, Zanoteli E (2018) Clinical, histological, and immunohistochemical findings in inclusion body myositis. Biomed Res Int 2018:5069042. https://doi.org/10.1155/2018/5069042
doi: 10.1155/2018/5069042
pubmed: 29780824
pmcid: 5893008
Demortier J, Vautier M, Chosidow O, Gallay L, Bessis D, Berezne A et al (2023) Anti-SAE autoantibody in dermatomyositis: original comparative study and review of the literature. Rheumatology (Oxford). https://doi.org/10.1093/rheumatology/kead154
doi: 10.1093/rheumatology/kead154
pubmed: 37010495
Dowling JJ, Moore SA, Kalimo H, Minassian BA (2015) X-linked myopathy with excessive autophagy: a failure of self-eating. Acta Neuropathol 129:383–390. https://doi.org/10.1007/s00401-015-1393-4
doi: 10.1007/s00401-015-1393-4
pubmed: 25644398
Elkon KB, Stone VV (2011) Type I interferon and systemic lupus erythematosus. J Interferon Cytokine Res 31:803–812. https://doi.org/10.1089/jir.2011.0045
doi: 10.1089/jir.2011.0045
pubmed: 21859344
pmcid: 3216059
Ellezam B, Leclair V, Troyanov Y, Bersali I, Giannini M, Hoa S et al (2022) Capillary pathology with prominent basement membrane reduplication is the hallmark histopathological feature of scleromyositis. Neuropathol Appl Neurobiol 48:e12840. https://doi.org/10.1111/nan.12840
doi: 10.1111/nan.12840
pubmed: 35894636
Ellezam B, Leclair V, Troyanov Y, Meyer A, Hudson M, Landon-Cardinal O (2021) Capillary basement membrane reduplication in myositis patients with mild clinical features of systemic sclerosis supports the concept of “scleromyositis.” Acta Neuropathol 142:395–397. https://doi.org/10.1007/s00401-021-02335-x
doi: 10.1007/s00401-021-02335-x
pubmed: 34115197
Engel AG, Arahata K (1987) The membrane attack complex of complement at the endplate in myasthenia gravis. Ann N Y Acad Sci 505:326–332. https://doi.org/10.1111/j.1749-6632.1987.tb51301.x
doi: 10.1111/j.1749-6632.1987.tb51301.x
pubmed: 3318619
Essouma M, Noubiap JJ, Singwe-Ngandeu M, Hachulla E (2022) Epidemiology of idiopathic inflammatory myopathies in Africa: a contemporary systematic review. J Clin Rheumatol 28:e552–e562. https://doi.org/10.1097/RHU.0000000000001736
doi: 10.1097/RHU.0000000000001736
pubmed: 33843773
Fischer N, Preuße C, Radke J, Pehl D, Allenbach Y, Schneider U et al (2020) Sequestosome-1 (p62) expression reveals chaperone-assisted selective autophagy in immune-mediated necrotizing myopathies. Brain Pathol 30:261–271. https://doi.org/10.1111/bpa.12772
doi: 10.1111/bpa.12772
pubmed: 31376301
Giannini M, Ellezam B, Leclair V, Lefebvre F, Troyanov Y, Hudson M et al (2023) Scleromyositis: a distinct novel entity within the systemic sclerosis and autoimmune myositis spectrum. Implications for care and pathogenesis. Front Immunol 13:974078. https://doi.org/10.3389/fimmu.2022.974078
doi: 10.3389/fimmu.2022.974078
pubmed: 36776390
pmcid: 9910219
Goebels N, Michaelis D, Wekerle H, Hohlfeld R (1992) Human myoblasts as antigen-presenting cells. J Immunol 149:661–667. https://doi.org/10.4049/jimmunol.149.2.661
doi: 10.4049/jimmunol.149.2.661
pubmed: 1352532
Greenberg SA (2010) Dermatomyositis and type 1 interferons. Curr Rheumatol Rep 12:198–203. https://doi.org/10.1007/s11926-010-0101-6
doi: 10.1007/s11926-010-0101-6
pubmed: 20425524
pmcid: 2929916
Greenberg SA (2019) Inclusion body myositis: clinical features and pathogenesis. Nat Rev Rheumatol 15:257–272. https://doi.org/10.1038/s41584-019-0186-x
doi: 10.1038/s41584-019-0186-x
pubmed: 30837708
Hida A, Yamashita T, Hosono Y, Inoue M, Kaida K, Kadoya M et al (2016) Anti-TIF1-γ antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology 87:299–308. https://doi.org/10.1212/WNL.0000000000002863
doi: 10.1212/WNL.0000000000002863
pubmed: 27343066
Hoffmann S, Harms L, Schuelke M, Rückert J-C, Goebel H-H, Stenzel W et al (2020) Complement deposition at the neuromuscular junction in seronegative myasthenia gravis. Acta Neuropathol 139:1119–1122. https://doi.org/10.1007/s00401-020-02147-5
doi: 10.1007/s00401-020-02147-5
pubmed: 32157386
pmcid: 7244604
Howard JF, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16:976–986. https://doi.org/10.1016/S1474-4422(17)30369-1
doi: 10.1016/S1474-4422(17)30369-1
pubmed: 29066163
Kölbel H, Preuße C, Brand L, von Moers A, Della Marina A, Schuelke M et al (2021) Inflammation, fibrosis and skeletal muscle regeneration in LGMDR9 are orchestrated by macrophages. Neuropathol Appl Neurobiol 47:856–866. https://doi.org/10.1111/nan.12730
doi: 10.1111/nan.12730
pubmed: 33973272
Komaki H, Hayashi YK, Tsuburaya R, Sugie K, Kato M, Nagai T et al (2011) Inflammatory changes in infantile-onset LMNA-associated myopathy. Neuromuscul Disord 21:563–568. https://doi.org/10.1016/j.nmd.2011.04.010
doi: 10.1016/j.nmd.2011.04.010
pubmed: 21632249
Kulski JK, Shiina T, Dijkstra JM (2019) Genomic diversity of the major histocompatibility complex in health and disease. Cells 8:1270. https://doi.org/10.3390/cells8101270
doi: 10.3390/cells8101270
pubmed: 31627481
pmcid: 6830316
Lahoria R, Selcen D, Engel AG (2016) Microvascular alterations and the role of complement in dermatomyositis. Brain 139:1891–1903. https://doi.org/10.1093/brain/aww122
doi: 10.1093/brain/aww122
pubmed: 27190020
De Lorenzo R, Pinal-Fernandez I, Huang W, Albayda J, Tiniakou E, Johnson C et al (2018) Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies. Neurology 90:e2068–e2076. https://doi.org/10.1212/WNL.0000000000005638
doi: 10.1212/WNL.0000000000005638
pubmed: 29728522
pmcid: 5993182
Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M et al (2017) EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76:1955–1964. https://doi.org/10.1136/annrheumdis-2017-211468
doi: 10.1136/annrheumdis-2017-211468
pubmed: 29079590
Lundberg IE, de Visser M, Werth VP (2018) Classification of myositis. Nat Rev Rheumatol 14:269–278. https://doi.org/10.1038/nrrheum.2018.41
doi: 10.1038/nrrheum.2018.41
pubmed: 29651121
Mair D, Biskup S, Kress W, Abicht A, Brück W, Zechel S et al (2020) Differential diagnosis of vacuolar myopathies in the NGS era. Brain Pathol 30:877–896. https://doi.org/10.1111/bpa.12864
doi: 10.1111/bpa.12864
pubmed: 32419263
pmcid: 8017999
Mammen AL, Allenbach Y, Stenzel W, Benveniste O, ENMC 239th Workshop Study Group (2020) 239th ENMC International Workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14–16 December 2018. Neuromuscul Disord 30:70–92. https://doi.org/10.1016/j.nmd.2019.10.005
doi: 10.1016/j.nmd.2019.10.005
pubmed: 31791867
Mammen AL, Amato AA, Dimachkie MM, Chinoy H, Hussain Y, Lilleker JB et al (2023) Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial. Lancet Rheumatol 5:e67–e76. https://doi.org/10.1016/s2665-9913(23)00003-6
doi: 10.1016/s2665-9913(23)00003-6
pubmed: 36923454
Mendell JR, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S et al (2010) Dystrophin immunity in Duchenne’s muscular dystrophy. N Engl J Med 363:1429–1437. https://doi.org/10.1056/NEJMoa1000228
doi: 10.1056/NEJMoa1000228
pubmed: 20925545
pmcid: 3014106
Meyer A, Meyer N, Schaeffer M, Gottenberg J-E, Geny B, Sibilia J (2015) Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology 54:50–63. https://doi.org/10.1093/rheumatology/keu289
doi: 10.1093/rheumatology/keu289
pubmed: 25065005
Miller FW, Cooper RG, Vencovský J, Rider LG, Danko K, Wedderburn LR et al (2013) Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum 65:3239–3247. https://doi.org/10.1002/art.38137
doi: 10.1002/art.38137
pubmed: 23983088
pmcid: 3934004
Müller TJ, Kraya T, Stoltenburg-Didinger G, Hanisch F, Kornhuber M, Stoevesandt D et al (2014) Phenotype of matrin-3-related distal myopathy in 16 German patients. Ann Neurol 76:669–680. https://doi.org/10.1002/ana.24255
doi: 10.1002/ana.24255
pubmed: 25154462
Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I et al (2019) Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve 60:14–24. https://doi.org/10.1002/mus.26447
doi: 10.1002/mus.26447
pubmed: 30767274
pmcid: 6619057
Nagaraju K, Raben N, Loeffler L, Parker T, Rochon PJ, Lee E et al (2000) Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci USA 97:9209–9214
doi: 10.1073/pnas.97.16.9209
pubmed: 10922072
pmcid: 16847
Napolitano F, Terracciano C, Bruno G, De Blasiis P, Lombardi L, Gialluisi A et al (2021) Novel autophagic vacuolar myopathies: phenotype and genotype features. Neuropathol Appl Neurobiol 47:664–678. https://doi.org/10.1111/nan.12690
doi: 10.1111/nan.12690
pubmed: 33393119
Neefjes J, Jongsma MLM, Paul P, Bakke O (2011) Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol 11:823–836. https://doi.org/10.1038/nri3084
doi: 10.1038/nri3084
pubmed: 22076556
Nelke C, Kleefeld F, Preusse C, Ruck T, Stenzel W (2022) Inclusion body myositis and associated diseases: an argument for shared immune pathologies. Acta Neuropathol Commun 10:84. https://doi.org/10.1186/s40478-022-01389-6
doi: 10.1186/s40478-022-01389-6
pubmed: 35659120
pmcid: 9164382
Nelke C, Schroeter CB, Stascheit F, Huntemann N, Pawlitzki M, Willison AG et al (2023) Eculizumab treatment alters the proteometabolome beyond the inhibition of complement. JCI Insight. https://doi.org/10.1172/jci.insight.169135
doi: 10.1172/jci.insight.169135
pubmed: 37227781
pmcid: 10371336
Nelke C, Schroeter CB, Stascheit F, Pawlitzki M, Regner-Nelke L, Huntemann N et al (2022) Eculizumab versus rituximab in generalised myasthenia gravis. J Neurol Neurosurg Psychiatry 93:548–554. https://doi.org/10.1136/jnnp-2021-328665
doi: 10.1136/jnnp-2021-328665
pubmed: 35246490
Nelke C, Stascheit F, Eckert C, Pawlitzki M, Schroeter CB, Huntemann N et al (2022) Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients. J Neuroinflammation 19:89. https://doi.org/10.1186/s12974-022-02448-4
doi: 10.1186/s12974-022-02448-4
pubmed: 35413850
pmcid: 9005160
Nguyen M, Do V, Yell PC, Jo C, Liu J, Burns DK et al (2020) Distinct tissue injury patterns in juvenile dermatomyositis auto-antibody subgroups. Acta Neuropathol Commun 8:125. https://doi.org/10.1186/s40478-020-01007-3
doi: 10.1186/s40478-020-01007-3
pubmed: 32758284
pmcid: 7405369
Noguchi E, Uruha A, Suzuki S, Hamanaka K, Ohnuki Y, Tsugawa J et al (2017) Skeletal muscle involvement in antisynthetase syndrome. JAMA Neurol 74:992–999. https://doi.org/10.1001/jamaneurol.2017.0934
doi: 10.1001/jamaneurol.2017.0934
pubmed: 28586844
pmcid: 5710328
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. https://doi.org/10.1136/bmj.n71
doi: 10.1136/bmj.n71
pubmed: 33782057
pmcid: 8479591
Pehl D, Preuße C, Allenbach Y, Benveniste O, Dittert P, Alten R et al (2023) Eosinophilic fasciitis (Shulman syndrome)-recognition of the histological spectrum allows for new insights into possible pathomechanisms. Rheumatology (Oxford) 62:2005–2014. https://doi.org/10.1093/rheumatology/keac526
doi: 10.1093/rheumatology/keac526
pubmed: 36130069
Pinal-Fernandez I, Casal-Dominguez M, Mammen AL (2018) Immune-mediated necrotizing myopathy. Curr Rheumatol Rep 20:21. https://doi.org/10.1007/s11926-018-0732-6
doi: 10.1007/s11926-018-0732-6
pubmed: 29582188
pmcid: 6019613
Pinal-Fernandez I, Quintana A, Milisenda JC, Casal-Dominguez M, Muñoz-Braceras S, Derfoul A et al (2023) Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis. Ann Rheum Dis 82:829–836. https://doi.org/10.1136/ard-2022-223792
doi: 10.1136/ard-2022-223792
pubmed: 36801811
Preusse C, Eede P, Heinzeling L, Freitag K, Koll R, Froehlich W et al (2021) Nanostring technology distinguishes anti-TIF-1γ+ from anti-Mi-2+ dermatomyositis patients. Brain Pathol 31:e12957. https://doi.org/10.1111/bpa.12957
doi: 10.1111/bpa.12957
pubmed: 34043263
pmcid: 8412076
Preuße C, Goebel HH, Held J, Wengert O, Scheibe F, Irlbacher K et al (2012) Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile. Am J Pathol 181:2161–2171. https://doi.org/10.1016/j.ajpath.2012.08.033
doi: 10.1016/j.ajpath.2012.08.033
pubmed: 23058368
Preuße C, Paesler B, Nelke C, Cengiz D, Müntefering T, Roos A et al (2022) Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis. Acta Neuropathol. https://doi.org/10.1007/s00401-022-02438-z
doi: 10.1007/s00401-022-02438-z
pubmed: 35612662
pmcid: 9288384
Reis ES, Mastellos DC, Hajishengallis G, Lambris JD (2019) New insights into the immune functions of complement. Nat Rev Immunol 19:503–516. https://doi.org/10.1038/s41577-019-0168-x
doi: 10.1038/s41577-019-0168-x
pubmed: 31048789
pmcid: 6667284
Rigolet A, Musset L, Dubourg O, Maisonobe T, Grenier P, Charuel J-L et al (2012) Inflammatory myopathies with anti-Ku antibodies: a prognosis dependent on associated lung disease. Medicine (Baltimore) 91:95–102. https://doi.org/10.1097/MD.0b013e31824d9cec
doi: 10.1097/MD.0b013e31824d9cec
pubmed: 22391471
Rivner MH, Quarles BM, Pan J, Yu Z, Howard JF, Corse A et al (2020) Clinical features of LRP4/agrin-antibody-positive myasthenia gravis: a multicenter study. Muscle Nerve 62:333–343. https://doi.org/10.1002/mus.26985
doi: 10.1002/mus.26985
pubmed: 32483837
pmcid: 7496236
Rodolico C, Bonanno C, Toscano A, Vita G (2020) MuSK-associated myasthenia gravis: clinical features and management. Front Neurol 11:660. https://doi.org/10.3389/fneur.2020.00660
doi: 10.3389/fneur.2020.00660
pubmed: 32793097
pmcid: 7390870
Roos A, Preusse C, Hathazi D, Goebel H-H, Stenzel W (2019) Proteomic profiling unravels a key role of specific macrophage subtypes in sporadic inclusion body myositis. Front Immunol 10:1040
doi: 10.3389/fimmu.2019.01040
pubmed: 31143183
pmcid: 6522546
Rothwell S, Chinoy H, Lamb JA, Miller FW, Rider LG, Wedderburn LR et al (2019) Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Ann Rheum Dis 78:996–1002. https://doi.org/10.1136/annrheumdis-2019-215046
doi: 10.1136/annrheumdis-2019-215046
pubmed: 31138531
Ruck T, Bittner S, Afzali AM, Göbel K, Glumm S, Kraft P et al (2015) The NKG2D-IL-15 signaling pathway contributes to T-cell mediated pathology in inflammatory myopathies. Oncotarget 6:43230–43243. https://doi.org/10.18632/oncotarget.6462
doi: 10.18632/oncotarget.6462
pubmed: 26646698
pmcid: 4791228
Salem J-E, Bretagne M, Abbar B, Leonard-Louis S, Ederhy S, Redheuil A et al (2023) Abatacept/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis. Cancer Discov 13:1100–1115. https://doi.org/10.1158/2159-8290.CD-22-1180
doi: 10.1158/2159-8290.CD-22-1180
pubmed: 36815259
Sasai T, Nakashima R, Shirakashi M, Hiwa R, Tsuji H, Kitagori K et al (2023) A new autoantibody to valyl transfer RNA synthetase associated with anti-synthetase syndrome. Rheumatology (Oxford) 62:e155–e157. https://doi.org/10.1093/rheumatology/keac569
doi: 10.1093/rheumatology/keac569
pubmed: 36193992
Saxena A, Stevens J, Cetin H, Koneczny I, Webster R, Lazaridis K et al (2017) Characterization of an anti-fetal AChR monoclonal antibody isolated from a myasthenia gravis patient. Sci Rep 7:14426. https://doi.org/10.1038/s41598-017-14350-8
doi: 10.1038/s41598-017-14350-8
pubmed: 29089519
pmcid: 5663942
Shiraishi H, Motomura M, Yoshimura T, Fukudome T, Fukuda T, Nakao Y et al (2005) Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 57:289–293. https://doi.org/10.1002/ana.20341
doi: 10.1002/ana.20341
pubmed: 15668981
Siegert E, Uruha A, Goebel H-H, Preuße C, Casteleyn V, Kleefeld F et al (2021) Systemic sclerosis-associated myositis features minimal inflammation and characteristic capillary pathology. Acta Neuropathol 141:917–927. https://doi.org/10.1007/s00401-021-02305-3
doi: 10.1007/s00401-021-02305-3
pubmed: 33864496
pmcid: 8113184
Spuler S, Engel AG (1998) Unexpected sarcolemmal complement membrane attack complex deposits on nonnecrotic muscle fibers in muscular dystrophies. Neurology 50:41–46. https://doi.org/10.1212/WNL.50.1.41
doi: 10.1212/WNL.50.1.41
pubmed: 9443455
Stenzel W, Preuße C, Allenbach Y, Pehl D, Junckerstorff R, Heppner FL et al (2015) Nuclear actin aggregation is a hallmark of anti-synthetase syndrome-induced dysimmune myopathy. Neurology 84:1346–1354. https://doi.org/10.1212/WNL.0000000000001422
doi: 10.1212/WNL.0000000000001422
pubmed: 25746564
Tanboon J, Inoue M, Hirakawa S, Tachimori H, Hayashi S, Noguchi S et al (2023) Muscle pathology of antisynthetase syndrome according to antibody subtypes. Brain Pathol 33:e13155. https://doi.org/10.1111/bpa.13155
doi: 10.1111/bpa.13155
pubmed: 36882048
pmcid: 10307527
Tanboon J, Inoue M, Saito Y, Tachimori H, Hayashi S, Noguchi S et al (2022) Dermatomyositis: muscle pathology according to antibody subtypes. Neurology 98:e739–e749. https://doi.org/10.1212/WNL.0000000000013176
doi: 10.1212/WNL.0000000000013176
pubmed: 34873015
pmcid: 8865893
Tanboon J, Nishino I (2022) Update on dermatomyositis. Curr Opin Neurol 35:611–621. https://doi.org/10.1097/WCO.0000000000001091
doi: 10.1097/WCO.0000000000001091
pubmed: 35942671
Tanboon J, Uruha A, Arahata Y, Dittmayer C, Schweizer L, Goebel H-H et al (2021) Inflammatory features in sporadic late-onset nemaline myopathy are independent from monoclonal gammopathy. Brain Pathol 31:e12962. https://doi.org/10.1111/bpa.12962
doi: 10.1111/bpa.12962
pubmed: 34043258
pmcid: 8412091
Tanboon J, Uruha A, Stenzel W, Nishino I (2020) Where are we moving in the classification of idiopathic inflammatory myopathies? Curr Opin Neurol 33:590–603. https://doi.org/10.1097/WCO.0000000000000855
doi: 10.1097/WCO.0000000000000855
pubmed: 32852298
Tiniakou E, Goldman D, Corse A, Mammen A, Petri MA (2022) Clinical and histopathological features of myositis in systemic lupus erythematosus. Lupus Sci Med 9:e000635. https://doi.org/10.1136/lupus-2021-000635
doi: 10.1136/lupus-2021-000635
pubmed: 35351810
pmcid: 8966527
Toquet C, Hamidou MA, Renaudin K, Jarry A, Foulc P, Barbarot S et al (2003) In situ immunophenotype of the inflammatory infiltrate in eosinophilic fasciitis. J Rheumatol 30:1811–1815
pubmed: 12913939
Touat M, Maisonobe T, Knauss S, Ben Hadj Salem O, Hervier B, Auré K et al (2018) Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology 91:e985–e994. https://doi.org/10.1212/WNL.0000000000006124
doi: 10.1212/WNL.0000000000006124
pubmed: 30089619
Udd B, Stenzel W, Oldfors A, Olivé M, Romero N, Lammens M et al (2019) 1st ENMC European meeting: the EURO-NMD pathology working group recommended standards for muscle pathology Amsterdam, The Netherlands, 7 December 2018. Neuromuscul Disord 29:483–485. https://doi.org/10.1016/j.nmd.2019.03.002
doi: 10.1016/j.nmd.2019.03.002
pubmed: 31101462
Uruha A, Allenbach Y, Charuel J-L, Musset L, Aussy A, Boyer O et al (2019) Diagnostic potential of sarcoplasmic myxovirus resistance protein A expression in subsets of dermatomyositis. Neuropathol Appl Neurobiol 45:513–522. https://doi.org/10.1111/nan.12519
doi: 10.1111/nan.12519
pubmed: 30267437
Uruha A, Nishikawa A, Tsuburaya RS, Hamanaka K, Kuwana M, Watanabe Y et al (2017) Sarcoplasmic MxA expression: a valuable marker of dermatomyositis. Neurology 88:493–500. https://doi.org/10.1212/WNL.0000000000003568
doi: 10.1212/WNL.0000000000003568
pubmed: 28039312
van der Pas J, Hengstman GJD, ter Laak HJ, Borm GF, van Engelen BGM (2004) Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies. J Neurol Neurosurg Psychiatry 75:136–139
pubmed: 14707323
pmcid: 1757482
Vidarsson G, Dekkers G, Rispens T (2014) IgG subclasses and allotypes: from structure to effector functions. Front Immunol. https://doi.org/10.3389/fimmu.2014.00520
doi: 10.3389/fimmu.2014.00520
pubmed: 25368619
pmcid: 4202688
Vissing J (2016) Limb girdle muscular dystrophies: classification, clinical spectrum and emerging therapies. Curr Opin Neurol 29:635–641. https://doi.org/10.1097/WCO.0000000000000375
doi: 10.1097/WCO.0000000000000375
pubmed: 27490667
Vu T, Meisel A, Mantegazza R, Annane D, Katsuno M, Aguzzi R et al (2022) Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. https://doi.org/10.1056/EVIDoa2100066
doi: 10.1056/EVIDoa2100066
Vulsteke J-B, Derua R, Dubucquoi S, Coutant F, Sanges S, Goncalves D et al (2022) Mass spectrometry-based identification of new anti-Ly and known antisynthetase autoantibodies. Ann Rheum Dis 82:546–555. https://doi.org/10.1136/ard-2022-222686
doi: 10.1136/ard-2022-222686
pubmed: 36572507
Watanabe Y, Uruha A, Suzuki S, Nakahara J, Hamanaka K, Takayama K et al (2016) Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry 87:1038–1044. https://doi.org/10.1136/jnnp-2016-313166
doi: 10.1136/jnnp-2016-313166
pubmed: 27147697
Wollman AJM, Nudd R, Hedlund EG, Leake MC (2015) From animaculum to single molecules: 300 years of the light microscope. Open Biol 5:150019. https://doi.org/10.1098/rsob.150019
doi: 10.1098/rsob.150019
pubmed: 25924631
pmcid: 4422127
Yang H, Tian X, Zhang L, Li W, Liu Q, Jiang W et al (2022) Clinical and pathological features of immune-mediated necrotising myopathies in a single-centre muscle biopsy cohort. BMC Musculoskelet Disord 23:425. https://doi.org/10.1186/s12891-022-05372-z
doi: 10.1186/s12891-022-05372-z
pubmed: 35524238
pmcid: 9074315